source
- Novo Nordisk loses bid to dismiss lawsuit over CagriSema trial readoutU.S. District Judge Robert Kirsch in New Jersey refused to dismiss most of the securities lawsuit filed by investors after Novo Nordisk’s CagriSema readout. While the judge found the plaintiffs’ cl…
- Processa Pharma acquires Vidya Therapeutics, gaining oral BTK inhibitor VT-7208Processa Pharmaceuticals announced an all‑stock acquisition of Vidya Therapeutics, a Florida biotech developing an oral BTK inhibitor called VT‑7208. VT‑7208 is being positioned as a next‑generati…